210 related articles for article (PubMed ID: 28262115)
21. Solubility-Permeability Interplay in Facilitating the Prediction of Drug Disposition Routes, Extent of Absorption, Food Effects, Brain Penetration and Drug Induced Liver Injury Potential.
Benet LZ
J Pharm Sci; 2023 Sep; 112(9):2326-2331. PubMed ID: 37429358
[TBL] [Abstract][Full Text] [Related]
22. Comparative Oral Drug Classification Systems: Acetazolamide, Azithromycin, Clopidogrel, and Efavirenz Case Studies.
Mora MJ; Onnainty R; Granero GE
Mol Pharm; 2018 Aug; 15(8):3187-3196. PubMed ID: 29927606
[TBL] [Abstract][Full Text] [Related]
23. Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data.
Heimbach T; Xia B; Lin TH; He H
AAPS J; 2013 Jan; 15(1):143-58. PubMed ID: 23139017
[TBL] [Abstract][Full Text] [Related]
24. The use of drug metabolism for prediction of intestinal permeability (dagger).
Chen ML; Yu L
Mol Pharm; 2009; 6(1):74-81. PubMed ID: 19132929
[TBL] [Abstract][Full Text] [Related]
25. Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts.
Camenisch GP
Pharm Res; 2016 Nov; 33(11):2583-93. PubMed ID: 27439505
[TBL] [Abstract][Full Text] [Related]
26. Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System.
Bowman CM; Benet LZ
Drug Metab Dispos; 2016 Nov; 44(11):1731-1735. PubMed ID: 27519549
[TBL] [Abstract][Full Text] [Related]
27. Improving the prediction of the brain disposition for orally administered drugs using BDDCS.
Broccatelli F; Larregieu CA; Cruciani G; Oprea TI; Benet LZ
Adv Drug Deliv Rev; 2012 Jan; 64(1):95-109. PubMed ID: 22261306
[TBL] [Abstract][Full Text] [Related]
28. Novel high/low solubility classification methods for new molecular entities.
Dave RA; Morris ME
Int J Pharm; 2016 Sep; 511(1):111-126. PubMed ID: 27349790
[TBL] [Abstract][Full Text] [Related]
29. Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS.
Garrison KL; Sahin S; Benet LZ
J Pharm Sci; 2015 Sep; 104(9):3229-35. PubMed ID: 26010239
[TBL] [Abstract][Full Text] [Related]
30. Computational models to assign biopharmaceutics drug disposition classification from molecular structure.
Khandelwal A; Bahadduri PM; Chang C; Polli JE; Swaan PW; Ekins S
Pharm Res; 2007 Dec; 24(12):2249-62. PubMed ID: 17846869
[TBL] [Abstract][Full Text] [Related]
31. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.
Benet LZ
J Pharm Sci; 2013 Jan; 102(1):34-42. PubMed ID: 23147500
[TBL] [Abstract][Full Text] [Related]
32. Keeping a critical eye on the science and the regulation of oral drug absorption: a review.
Macheras P; Karalis V; Valsami G
J Pharm Sci; 2013 Sep; 102(9):3018-36. PubMed ID: 23568812
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of
Chan R; Benet LZ
Toxicol Res (Camb); 2018 May; 7(3):358-370. PubMed ID: 29785262
[TBL] [Abstract][Full Text] [Related]
34. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
35. iBCS: 3. A Biopharmaceutics Classification System for Orally Inhaled Drug Products.
Hastedt JE; Bäckman P; Cabal A; Clark A; Ehrhardt C; Forbes B; Hickey AJ; Hochhaus G; Jiang W; Kassinos S; Kuehl PJ; Prime D; Son YJ; Teague S; Tehler U; Wylie J
Mol Pharm; 2024 Jan; 21(1):164-172. PubMed ID: 38059771
[TBL] [Abstract][Full Text] [Related]
36. Reconciling Human-Canine Differences in Oral Bioavailability: Looking beyond the Biopharmaceutics Classification System.
Martinez MN; El-Kattan A; Awji E; Papich M
AAPS J; 2019 Aug; 21(5):99. PubMed ID: 31396733
[TBL] [Abstract][Full Text] [Related]
37. The utility of rat jejunal permeability for biopharmaceutics classification system.
Zakeri-Milani P; Valizadeh H; Tajerzadeh H; Islambulchilar Z
Drug Dev Ind Pharm; 2009 Dec; 35(12):1496-502. PubMed ID: 19929209
[TBL] [Abstract][Full Text] [Related]
38. Evaluating Solubility of Celecoxib in Age-Appropriate Fasted- and Fed-State Gastric and Intestinal Biorelevant Media Representative of Adult and Pediatric Patients: Implications on Future Pediatric Biopharmaceutical Classification System.
Shawahna R; Zyoud A; Haj-Yahia A; Taya R
AAPS PharmSciTech; 2021 Mar; 22(3):84. PubMed ID: 33649887
[TBL] [Abstract][Full Text] [Related]
39. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
[TBL] [Abstract][Full Text] [Related]
40. In Situ Intestinal Perfusion in Rodents: Future Perspectives for Application on Absorption Studies and Classification of Drugs.
Dezani TM; Dezani AB; de Silva MMC; Dos Reis Serra CH
Mini Rev Med Chem; 2017; 17(9):746-757. PubMed ID: 27659249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
